Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 16;12(2):185-189.
doi: 10.1055/s-0042-1748184. eCollection 2023 Apr.

Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India

Nitin Sood  1 , Aseem Kumar Tiwari  2 , Swati Pabbi  2 , Roshan Dikshit  1 , Prerna Singh  1 , Amrita Ramaswami  3 , Dheeraj Gautam  4 , Manish Kumar Singh  5
Affiliations

Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India

Nitin Sood et al. South Asian J Cancer. .

Abstract

Swati PabbiIntroduction Multiple myeloma (MM) forms a significant proportion of hematological malignancies. Autologous transplantation continues to be an effective consolidation strategy in resource-restricted settings such as India. Objectives The main objective of the study was to analyze the clinical outcomes of autologous hematopoietic stem cell transplant (HSCT) in MM patients in a single tertiary care center in north India over a period of 5 years. Materials and Methods This retrospective observational study was conducted in a tertiary care center in north India. Data of all MM patients who underwent HSCT between January 2014, and December 2018, were analyzed. The outcome of HSCT was investigated in terms of transplant-related mortality (TRM), progression-free survival (PFS), overall survival (OS), and relapse. PFS and OS were calculated by Kaplan-Meier method and differences between the groups were tested for statistical significance using the two-tailed log-rank test. Life-table method was used for the estimation of survival rate at 1, 3, 5, and 6 years. Results Patient characteristics and survival post-transplant was similar to other published Indian studies. In total, 378 patients were diagnosed with MM in our hospital between 2014 and 2018. One hundred ninety-three patients were found to be eligible for autologous HSCT, out of which 52 ended up having a transplant giving us a high percentage (26.9%) of patients receiving a transplant in our setting. Transplant-related mortality (TRM) was nil in the present study. The mean PFS and OS were 62.8 and 70.1 months, respectively. The mean PFS and OS rates at 5 years were 75.3% and 84.2%, respectively. The average cost estimate of HSCT in our setting was 7.2 lakh Indian national rupees. Conclusion Autologous HSCT is a safe procedure with nil 100-day mortality in present series. Moreover, considering the cost of novel agents, autologous transplant remains a cost-effective way for prolonging remission and time-to-next treatment in India.

Keywords: autologous transplant; hematopoietic stem cell transplant; multiple myeloma; myeloma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

None
Swati Pabbi
Fig. 1
Fig. 1
Kaplan–Meier curve for overall survival.
Fig. 2
Fig. 2
Kaplan–Meier curve for progression-free survival.
See this image and copyright information in PMC

References

    1. Ludwig H, Durie B G, Bolejack V et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111(08):4039–4047. - PMC - PubMed
    1. Kumar S K, Rajkumar S V, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(05):2516–2520. - PMC - PubMed
    1. Cavo M, Baccarani M. The changing landscape of myeloma therapy. N Engl J Med. 2006;354(10):1076–1078. - PubMed
    1. Attal M, Harousseau J L, Stoppa A M et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335(02):91–97. - PubMed
    1. Medical Research Council Adult Leukaemia Working Party . Child J A, Morgan G J, Davies F E et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–1883. - PubMed